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Abstract 
Gaucher disease is the most common lysosomal storage disease. It is caused by the 
defective activity of acid β-glucosidase, which results in the accumulation of lipid 
glucocerebroside in macrophages throughout the body. In this case report we describe 
the case of a young adult woman with splenomegaly as the primary manifestation of this 
pathology. This is a case of type 1 Gaucher disease because there is a lack of primary 
neurological involvement but we have, instead, an age-independent involvement of the 
visceral organs. It is very important to classify or characterize these patients in a precise 
manner and to make a complete diagnosis with the help of the many diagnostic 
resources now at our disposal, especially with genetics, radiology and new techniques of 
advanced microscopy, also because Gaucher disease requires a long and complex 
management from early life to adulthood. 
 
Introduction 
Gaucher disease is the most common lysosomal storage disease [1, 2]. It is caused by 
the defective activity of acid β-glucosidase, which results in the accumulation of lipid 
glucocerebroside in macrophages throughout the body [3, 4]. There are many 
manifestations of Gaucher disease, such as hepatosplenomegaly, anemia, 
thrombocytopenia and bone marrow infiltration with characteristic storage cells, Gaucher  
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cells and bony lesions [5]. Three forms of Gaucher disease have been identified [6]. The 
most common form is type 1, characterized by a lack of primary neurological 
involvement but with involvement of the visceral organs to varying degrees. However, 
neurological involvement occurs early during disease progression in type 2 disease and 
later in type 3 disease. In fact types 2 and 3 have been termed acute and subacute 
neuronopathic, respectively, based on the rapidity of progression of central nervous 
system deterioration and at onset [7]. 
Case Report 
The patient, an 18-year-old woman, came under our observation due to the persistence, for more 
than six months, of widespread articular pain, especially during the night, easy fatigue and the 
occasional occurrence of thrombocytopenia. For these reasons she had already been to another hospital 
and a not better specified diagnosis of ‘autoimmune-based illness’ had been formulated, for which 
cyclosporine therapy was prescribed, pending a probable splenectomy. During the stay in our hospital 
the patient complained of bone pain, particularly articular and in the lower limbs, although to a lesser 
degree than before beginning the previously mentioned immunosuppressive therapy, and easy fatigue. 
No signs worth noting emerged from anamnesis. On objective examination the patient was found to be 
in a reasonably good general condition, alert and well oriented in time and space, with normal facies, 
negligible decubitus and no signs of bilateral peripheral edemas. The skin had a normal blood supply 
and was normally hydrated, and the subcutaneous panniculus adiposus was normally represented and 
distributed. The muscular mass was normotonic and normotrophic and the superficial lymph node 
system was undamaged. Locoregional objective examination was negative except for the presence of 
impressive splenomegaly. 
Specialist neurological objective examination was completely negative. The vital parameters 
monitored were normal. The results of the hematochemical examinations carried out were normal 
except for a slight enzymatic cholestasis (γ-Gt <2×) and a slight hypertriglyceridemia. Protein 
electrophoresis showed an insignificant increase in alpha-2 globulin and a slight reduction in beta-2 
globulin. Blood count showed hemoglobin equal to 10 g/dl, hematocrit equal to 29.4%, a red blood cell 
count of 3,720,000, a white blood cell count of 5,270, MCV equal to 79.1 fl and a platelet count of 
115,000. Blood coagulation tests showed a PT of 68.4% and an APTT of 37.80 s. Abdominal nuclear 
magnetic resonance imaging (NMRI) showed: ‘a considerably enlarged liver (cranio-caudal diameter 
24 cm); splenomegaly (cranio-caudal diameter 22 cm, transverse diameter 11 cm) with dilation of the 
spleen vein’. For a more in-depth diagnostic analysis the patient was subjected to a hepatic biopsy with 
the diagnosis of ‘hepatic tissue characterized by marked hypertrophy of Kupffer cells (PGM-1 positive 
to immunohistochemistry) with extensive cytoplasm with a wrinkled appearance, eosinophilic with PAS 
diastase staining: morphological report indicative of Gaucher disease’. Based on these results we carried 
out an analysis of the glucocerebrosidase gene through amplification of a DNA sequence (PCR), 
detecting the presence of the N370S mutation in both alleles. The genetic test was then carried out on 
the rest of the family. A skeletal X-ray of the patient showed that ‘the overall picture was within the 
norm except for the presence of structural alterations in the proximal metaphyseal and diaphyseal 
region of the right tibia, compatible with Gaucher disease’, and a DEXA study showed ‘particularly low 
BMD compared to normal limits for the same gender and age’. NMRI of the cranium was negative. On 
completion of the diagnostic procedure, as a result, the patient was discharged with enzymatic 
replacement therapy. 
The follow-up of this patient after a year of therapy indicates that her present condition is good, she 
has neither cholestasis nor hypertriglyceridemia and there is satisfactory reduction in splenomegaly, 
hypersplenism and articular pain. However we are planning to follow the patient for a long time. 
Discussion 
Certainly, apart from the general (fatigue, bone pain, etc.) or laboratory (anemia, 
thrombocytopenia, etc.) signs and suspected pathology detected by NMRI, as in this case, 
the diagnosis of Gaucher disease is established histologically by examining bone marrow 
or tissue from liver or spleen biopsies [8]. However histological diagnosis of Gaucher  
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disease is not always reliable because it is not easy to differentiate the abnormal 
macrophages, in fact other similar cells are present in hemorrhagic disorders, leukemia, 
lymphoma, osteomyelitis and Legg-Calvé-Perthes disease, in fact, finally the histological 
diagnosis of Gaucher requires an invasive procedure such as a bone marrow biopsy and 
only occasionally and unfortunately a liver or spleen biopsy is enough for diagnosis. 
An alternative approach used by us is that of DNA analysis [6]. Of more than 200 
different mutations identified in Gaucher disease patients, only five have any general 
frequency [4]. The N370S and L444P mutations have some predictive value and these 
mutant alleles account for about half of identified Gaucher disease patients of European 
descent. The N370S mutation is the most common mutation in the Ashkenazi Jewish 
variant of type 1 Gaucher disease and is the most frequent mutation found in such 
patients in North America and Europe. The presence of a single N370S allele predicts 
non-neuronopathic disease [9], whereas N370S allele in conjunction with another mutant 
allele predicts more severe disease; the L444P homozygous state has a very high 
association with the neuronopathic variants such as type 2 or 3 Gaucher disease [10–12]. 
To classify or characterize patients with this pathology, a physical and neurological 
examination is necessary to exclude the presence of strabismus, saccadic initiation 
abnormalities of the eye, opisthotonic posturing and bulbar palsy/paresis [4]. 
This case is a case of type 1 Gaucher disease because there is a lack of primary 
neurological involvement but we have, instead, an age-independent involvement of the 
visceral organs. Symptomatic children designated as type 1 can experience variably 
progressive hepatosplenomegaly and/or hematologic abnormalities; in fact 
thrombocytopenia is often an early finding and anemia is somewhat less common and 
usually mild [6]. Growth retardation is a common and often unappreciated sign without 
concordance with progression of hepatosplenomegaly, but our patient showed regular 
growth [13]. Hepatomegaly can be severe and splenomegaly is present in most patients 
and may be marked [14], as in our case. 
Osteopenia and osteoporosis have become increasingly diagnosed in recent years, 
especially in children, but osteoporosis by DEXA during puberty is very important. The 
skeletal involvement of Gaucher disease is characterized by the infiltration of bone 
marrow [15] with possible edema or ischemia, osteopenia with an abnormal decrease in 
mineral bone density and bone mass, localized or diffuse, Erlenmeyer flask deformity, 
osteonecrosis with bone death caused by chronic ischemic events and associated with 
acute pain, bone crisis that is a severe weakening episodic manifestation with a high fever, 
pathological fractures, general bone pain and asymptomatic growth retardation. The 
development of skeletal involvement in Gaucher disease is present in several ethnic 
groups as Ashkenazi Jewish, Dutch and Japanese. 
For the treatment of Gaucher disease physicians were faced with the difficulty of 
treating patients before enzyme replacement therapy became available by ensuring the 
patients with high quality of life [6]. Splenectomy is a possible measure for correcting 
thrombocytopenia, but today it is generally deferred as long as possible because of the 
suspicion that it accelerates the deposition of glycolipid at other sites, but the evidence is 
anecdotal, and also because the response to therapy in this sense is good and splenectomy 
is carried out much less frequently, but if thrombocytopenia does not respond quickly to 
enzyme replacement therapy, splenectomy may be in order. 
Recently the history of enzyme replacement therapy has been reviewed and there is no 
question that the therapy is effective, although it is extremely costly and the issue of  
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dosage is often controversial. Other studies, especially with chemical inhibitors of 
glucosylceramide synthase, are still in progress. 
Conclusions 
Although Gaucher disease is a rare disorder, today many specialists, especially 
pediatricians [4], identify and will continue to identify patients with this pathology in 
their practice, so it is very important to classify or characterize these patients in a precise 
manner, make a complete diagnosis with the help of the many diagnostic resources now 
at our disposal, especially with genetics, radiology and new techniques of advanced 
microscopy, also because Gaucher disease requires a long and complex management from 
early life to adulthood. 
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